Calorie Restriction Impairs Anti-Tumor Immune Responses in an Immunogenic Preclinical Cancer Model

被引:1
|
作者
Dung, Nguyen Tien [1 ,2 ]
Susukida, Takeshi [2 ]
Ucche, Sisca [2 ]
He, Ka [2 ]
Sasaki, So-ichiro [2 ]
Hayashi, Ryuji [1 ]
Hayakawa, Yoshihiro [2 ]
机构
[1] Univ Toyama, Toyama Univ Hosp, Dept Med Oncol, Toyama 9300194, Japan
[2] Univ Toyama, Inst Nat Med, Sect Host Def, Toyama 9300194, Japan
关键词
calorie restriction; host immune response; CD8(+) T cell; immune checkpoint inhibitor; OBESITY; PREVENTION; MECHANISMS; DIET; INFLAMMATION; ACTIVATION; OVERWEIGHT; NUTRITION; EXERCISE; BLOCKADE;
D O I
10.3390/nu15163638
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
(1) Background: Although the important role of dietary energy intake in regulating both cancer progression and host immunity has been widely recognized, it remains unclear whether dietary calorie restriction (CR) has any impact on anti-tumor immune responses. (2) Methods: Using an immunogenic B16 melanoma cell expressing ovalbumin (B16-OVA), we examined the effect of the CR diet on B16-OVA tumor growth and host immune responses. To further test whether the CR diet affects the efficacy of cancer immunotherapy, we examined the effect of CR against anti-PD-1 monoclonal antibody (anti-PD-1 Ab) treatment. (3) Results: The CR diet significantly slowed down the tumor growth of B16-OVA without affecting both CD4(+) and CD8(+) T cell infiltration into the tumor. Although in vivo depletion of CD8(+) T cells facilitated B16-OVA tumor growth in the control diet group, there was no significant change in the tumor growth in the CR diet group with or without CD8(+) T cell-depletion. Anti-PD-1 Ab treatment lost its efficacy to suppress tumor growth along with the activation and metabolic shift of CD8(+) T cells under CR condition. (4) Conclusions: Our present results suggest that a physical condition restricted in energy intake in cancer patients may impair CD8(+) T cell immune surveillance and the efficacy of immunotherapy.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Impact of calorie restriction on anti-tumor immune responses in the preclinical cancer model
    Nguyen, Dung T.
    CANCER SCIENCE, 2023, 114 : 1414 - 1414
  • [2] Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses
    Balogh, Kristen N.
    Templeton, Dennis J.
    Cross, Janet, V
    PLOS ONE, 2018, 13 (06):
  • [3] Lymphangiogenesis and Anti-Tumor Immune Responses
    Varney, Michelle L.
    Singh, Seema
    Backora, Matthew
    Chen, Zhengtang
    Singh, Rakesh K.
    CURRENT MOLECULAR MEDICINE, 2009, 9 (06) : 694 - 701
  • [4] The mechanisms on evasion of anti-tumor immune responses in gastric cancer
    Wang, Junyang
    Liu, Tong
    Huang, Tao
    Shang, Mei
    Wang, Xudong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] AAV-mediated induction of immunogenic cell death to promote anti-tumor immune responses
    Scarpitta, A.
    Hardet, R.
    Bentler, M.
    Demeules, M.
    Blandin, M.
    Hacker, U.
    Buening, H.
    Boyer, O.
    Adriouch, S.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A7 - A7
  • [6] LAG3 BLOCKADE IN COMBINATION WITH GITR IMPROVES ANTI-TUMOR IMMUNE RESPONSES IN A PRECLINICAL MELANOMA MODEL
    Maniyar, Rachana
    Zappasodi, Roberta
    Elhanati, Yuval
    St Jean, Samantha
    Carrasco, Sebastian
    Greenbaum, Benjamin
    Wolchok, Jedd
    Merghoub, Taha
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A881 - A881
  • [7] Anti-tumor Vaccines in head and neck cancer: Targeting immune responses to the tumor
    Whiteside, Theresa L.
    CURRENT CANCER DRUG TARGETS, 2007, 7 (07) : 633 - 642
  • [8] The role of cancer stem cells in the modulation of anti-tumor immune responses
    Maccalli, Cristina
    Rasul, Kakil Ibrahim
    Elawad, Mamoun
    Ferrone, Soldano
    SEMINARS IN CANCER BIOLOGY, 2018, 53 : 189 - 200
  • [9] Visualizing anti-tumor immune responses in vivo
    Perentes, Jean Y.
    Duda, Dan G.
    Jain, Rakesh K.
    DISEASE MODELS & MECHANISMS, 2009, 2 (3-4) : 107 - 110
  • [10] Role of Imiquimod in anti-tumor immune responses
    Drobits, B.
    Holcmann, M.
    Grundtner, R.
    Sibilia, M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 : 91 - 91